Mersana Therapeutics, Inc. Deferred Revenue Recognized
Mersana Therapeutics, Inc. reported Deferred Revenue Recognized of $4.53 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-11-14
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $4.53M, a 3.28% increase year-over-year.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $2.40M, a 4.71% increase year-over-year.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $2.16M, a 76.67% decline year-over-year.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $4.39M, a 2.55% decline year-over-year.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $27.31M, a 2.00% decline from fiscal 2023.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $27.87M, a 64713.95% increase from fiscal 2022.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $43.00K, a 0.00% change from fiscal 2021.
- Mersana Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $43.00K, a 94.81% decline from fiscal 2020.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-09-30 | $4.53M 10-Q · filed 2025-11-14 | $8.12M 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $2.40M 10-Q · filed 2025-08-13 | $4.56M 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $2.16M 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $27.31M 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $4.39M 10-Q · filed 2025-11-14 | $14.88M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $2.29M 10-Q · filed 2025-08-13 | $11.23M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $9.24M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $27.87M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $4.50M 10-Q · filed 2024-11-13 | $17.96M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $8.50M 10-Q · filed 2024-08-13 | $13.61M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $5.11M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $43.00K 10-K · filed 2024-02-28 | |||
| 2022-09-30 | $4.92M 10-Q · filed 2023-11-07 | $32.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $4.28M 10-Q · filed 2023-08-08 | $21.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $11.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $43.00K 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $11.00K 10-Q · filed 2021-11-09 | $32.00K 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | $11.00K 10-Q · filed 2021-08-06 | $21.00K 10-Q · filed 2021-08-06 | ||
| 2021-03-31 | $11.00K 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $828.00K 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $11.00K 10-Q · filed 2021-11-09 | $817.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $796.00K 10-Q · filed 2021-08-06 | $807.00K 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $11.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $41.59M 10-K · filed 2021-02-26 | |||
| 2019-09-30 | $834.00K 10-Q · filed 2020-11-09 | $41.55M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $123.00K 10-Q · filed 2020-08-07 | $40.72M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $40.59M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $8.70M 10-K · filed 2020-02-28 | |||
| 2018-09-30 | $1.76M 10-Q · filed 2019-11-06 | $7.51M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $2.69M 10-Q · filed 2019-08-08 | $5.75M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $3.06M 10-Q · filed 2018-05-15 |